Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Roche marketing presentation

3,962 views

Published on

Roche marketing presentation

Published in: Education
  • Making a living taking surveys at home! I have been a stay at home mom for almost 5 years and I am so excited to be able to still stay home, take care of my children and make a living taking surveys on my own computer! It's so easy to get started and I plan to make enough money each week so that my husband can actuallly quit his second job!!! Thank you so much! ●●● http://t.cn/AieXAuZz
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • High paying jobs on Facebook? $25 per hour, start immediately  https://tinyurl.com/rbrfd6j
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • The Scrambler Unlock Her Legs | 95% Off by Bobby Rio-Rob Judge? ♣♣♣ http://t.cn/AijLRbnO
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • How to start a wildly profitable 7 figure marketing business and get your first commission check tonight, click here ➤➤ http://ishbv.com/j1r2c/pdf
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Earn $90/day Working Online. You won't get rich, but it is going to make you some money! ➤➤ https://tinyurl.com/y4urott2
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Roche marketing presentation

  1. 1. Group Members Abdul Hamid Salman Anwar M. Yaqoob S M Owais Madiha Mushtaq Madiha Noor Quratulen Farukh Shareef Asmara
  2. 2. Introduction  Founded in 1896 by Fritz Hoffman-La Roche.  Headquarters are in Basel Switzer Land.  3rd largest Company all over the world.  Operates in 6 regions of the world.
  3. 3. Vision “Strengthen our leading position in diagnostics and shape the health information market by integrating test results and medical information to support medical decision- makers and superior patient management.”
  4. 4. Mission Our aim as a leading healthcare company is to create, produce, and market innovative solutions of high quality for unmet medical needs. Our mission is to create added value in healthcare by focusing on our expertise in Diagnostics and Pharmaceuticals. We aim to improve patient care by discovering, developing, manufacturing, and marketing innovative, high quality, cost-effective healthcare products and services.
  5. 5. Proposed Vision  To be the number 1 and most admired Health Care Company in the world.
  6. 6. Proposed Mission Modified Mission Statement: To deliver consistently superior products and services globally and nationally through combination of R&D ( advanced technology) and positive workforce, which contribute significantly to improving the quality of life for consumers. Gaps Market Technology Employees
  7. 7. HEIRARCHY
  8. 8. Roche Employees
  9. 9. Key Facts of Roche
  10. 10. Pipe Line Products
  11. 11. STAGE 1 : INPUT STAGE External Factor Evaluation Matrix (EFE) Opportunities Weight Rating Weighted Score Zarb-e-azab 0.05 3 0.15 Operation against corruption 0.04 2 0.08 66 New molecules are in Pipeline 0.07 4 0.28 Roche also working on rare disease 0.07 4 0.28 Personalized health care introduce in Pakistan and other countries. 0.03 3 0.09 Strategic opportunities may arise from Health IT and Big Data system of Roche 0.03 4 0.12 ‘Bhatta-Khori’ is lesser day by day which help Roche to increase profit margin 0.06 3 0.18 Developing innovative approaches in collaboration with international and local players 0.05 4 0.20 Roche make the strategic planning with African govt. and stakeholders for the availability of the innovative medicine. 0.03 2 0.06 Ranking of Roche is 5th among the Pharmaceuticals in world wide. 0.07 4 0.28
  12. 12. Threats Weight Rating Weighted Score Law and order situation. 0.06 3 0.18 R& D therats 0.08 4 0.32 Smuggling of medicine 0.06 4 0.24 Sustainability risk identified in 2014 report is cyber-attacks, Third party relationship, inadequate strategies for Cloud, m-Health (use of mobile devices), e-Health (Use of electronic Devices and Social media. 0.02 2 0.04 Imitation of products/ fake medicines supplied under brands name can affect brand 0.05 3 0.15 Fluctuation in dollar rates 0.04 3 0.12 Avastin receives negative response from the FDA for use in breast cancer treatment. 0.03 2 0.06 Regulatory environment is becoming more & more stringent 0.04 3 0.12 Hard to forecast external factors 0.07 4 0.28 loss of patent protection in developing countries 0.05 4 0.20 TOTALS 1.00 3.43
  13. 13. COMPETITIVE PROFILE MATRIX Competitive Profile Matrix (CPM) Roche Abbott Sanofi Critical Success Factors Weight Rating Scor e Rating Scor e Rating Scor e Advertising 0.03 1 0.03 2 0.06 1 0.03 Market Penetration 0.08 3 0.24 4 0.32 3 0.24 Marketing 0.02 1 0.02 2 0.04 1 0.02 Distribution Channels 0.13 3 0.39 3 0.39 3 0.39 R&D 0.14 4 0.56 4 0.56 2 0.28 Employee Dedication 0.07 3 0.21 2 0.14 3 0.21 Financial Profit 0.08 3 0.24 3 0.24 2 0.16 Customer Loyalty 0.09 3 0.27 2 0.18 3 0.27 Market Share 0.09 3 0.27 3 0.27 4 0.36 Product Quality 0.11 4 0.44 4 0.44 4 0.44 Top Management 0.06 2 0.12 3 0.18 2 0.12 Profit Margin 0.10 4 0.40 2 0.20 3 0.30 Totals 1.00 3.19 3.02 2.82
  14. 14. INTERNAL FACTOR EVALUATION Strengths Weight Rating Avg. Weighted Global presence 0.03 4 0.12 Providing high quality products 0.02 4 0.08 Efficient Management 0.08 4 0.32 Strategic Alliance and acquisitions 0.07 3 0.21 Patents 0.01 3 0.03 Diversified portfolio 0.02 3 0.06 Human resource 0.07 4 0.28 Continuous Improvements 0.06 3 0.18 Strong research and development 0.01 4 0.04 Weakness Distribution channel 0.03 2 0.06 Labor turnover 0.05 1 0.05 Decreasing market share 0.04 2 0.08 Internal control system 0.03 2 0.06 Lack of wide range of products 0.03 2 0.06 Threats of new entrants 0.09 2 0.18 Lack of wide area space 0.16 2 0.32 Less promotional and advertisement 0.2 2 0.4 Total weighted score 1 2.53
  15. 15. STAGE# THE MATCHING STAGE
  16. 16. SWOT Analysis STRENGTH 1. Roche Pakistan is 42% share and global share is about 28% 2. Brand heritage is high 3. Roche have very strong distribution network 4. 81% of the employee are proud to work with Roche. 5. Roche Pakistan is leading brand of glucometer .i.e. Accu-Chek and it is present in Pakistan since last 20 years it almost cover the 45% market of Glucometer in Pakistan 6. It is no # 1 in Biotech, Oncology, diagnostic and hospital marketing. In Pakistan and world wide 7. World most sustainable company in life sciences 8. Continuous product development 9. 4% Increase in Pharmaceutical sales from last year worldwide. 10. SHE safety, Security and environmental Protection is the integral part of Roche operations WEAKNESS 1. No local production. Roche products are imported so import cost is higher than the local production 2. Lack of coordination between industry and academia 3. No ATL activities .Roche is mostly involve in BTL activity. 4. Lack of infrastructure 5. Un-trained trained professionals 6. Lack of affordability 7. High internal pressure of cost adversely affects the developmental activities. OPPORTUNITY 1. Zarb-e-azb in Pakistan 2. Operation against corruption in Pakistan. 3. 66 New molecules are in Pipeline >30 cancer medicine are in clinical development 4. Roche also working on rare disease 5. Bhatta-Khori’ is lesser day by day which help Roche to increase profit margin. 6. developing innovative approaches in collaboration with international and local players 7. Ranking of Roche is 3rd among the Pharmaceuticals in world wide. Roche ranks world’s leading health care with two core expertise that is diagnostic and Pharmaceuticals. 8. Strategic opportunities may arise from Health IT and Big Data system of Roche. 9. Roche make the strategic planning with African govt. and stakeholders for the availability of the innovative medicine. 10. Personalized health care introduce in Pakistan and other countries. THREATS 1. Law and order situation. 2. R & D threats 3. Smuggling of medicine 4. Sustainability risk identified in 2014 report is cyber-attacks, Third party relationship, inadequate strategies for Cloud, m-Health (use of mobile devices), e-Health (Use of electronic Devices and Social media. 5. Imitation of products/ fake medicines supplied under brands name can affect brand. 6. Fluctuation in dollar rates 7. Avastin receives negative response from the FDA for use in breast cancer treatment. 8. Regulatory environment is becoming more & more stringent 9. Lose of patent protection in developing countrieS 10. Hard to forecast external factors
  17. 17. SWOT STRATEGIES SO 1.Penetration in KPK & Baluchistan .(S1,O1) 2. Penetration to other markets internationally (S1,O9) 3. New Product development in collaboration with international and local players (S3, O6) WO 1.New Infrastructure for local production (W4,O2) 2. Training of employees (W5,O7) WT 1.Inovolve academia for the development of new product development (W2,T7) 2.More research for epidemics and new illness by involving academia and continuous research to reduce the cost of production (W2,T2,T8) ST 1.Investment in continous product development (S8,T2) 2.Investment for the protection of cyber-attacks (S9,T4)
  18. 18. SPACE MATRIX Internal Analysis: External Analysis: Financial Position (FP) Stability Position (SP) Return on Investment (ROI) 5 Rate of Inflation -3 Leverage 5 Technological Changes -1 Liquidity 4 Price Elasticity of Demand -3 Working Capital 4 Competitive Pressure -3 Net Income 4 Barriers to Entry into Market -2 Financial Position (FP) Average 4.4 Stability Position (SP) Average -2.4 Internal Analysis: External Analysis: Competitive Position (CP) Industry Position (IP) Market Share -1 Growth Potential 5 Product Quality -1 Financial Stability 6 Customer Loyalty -2 Ease of Entry into Market 3 Technological know-how -1 Resource Utilization 6 Control over Suppliers and Distributors -2 Profit Potential 5 Competitive Position (CP) Average -1.4 Industry Position (IP) Average 5.0
  19. 19. SPACE MATRIX
  20. 20. Grand Strategy Matrix Rapid Market Growth Quadrant II Quadrant I 0 0 Weak Competitive Position Strong Competitive Position 0 Roche Quadrant III Quadrant IV Slow Market Growth
  21. 21. BCG MATRIX Cobas e 602 (2797 m) Accu Check Aviva (2159 m) Cobas 6800 (530 m) Kadsayla ( 536 m) Accu Chek Advantage Pegesus Avasting (6417 m) Hercepting (6274 m)
  22. 22. THIRD STAGE: DECISION STAGE QSPM
  23. 23. KPK Penetration Better employee programs to heighten perceived Value of salary, benefits, and self recognition Opportunities Weight AS TAS AS TAS Zarb-e-azab 0.05 4 0.20 2 0.10 Operation against corruption 0.04 2 0.08 3 0.12 66 New molecules are in Pipeline 0.07 3 0.21 3 0.21 Roche also working on rare disease 0.08 3 0.24 3 0.24 Personalized health care introduce in Pakistan and other countries. 0.03 4 0.12 4 0.12 Strategic opportunities may arise from Health IT and Big Data system of Roche 0.03 3 0.09 4 0.12 ‘Bhatta-Khori’ is lesser day by day which help Roche to increase profit margin 0.06 4 0.24 3 0.18 Developing innovative approaches in collaboration with international and local players 0.05 4 0.20 3 0.15 Roche make the strategic planning with African govt. and stakeholders for the availability of the innovative medicine. 0.03 2 0.06 3 0.09 Roche's partnership with local companies in India and China to commercialize its drug Tamiflu. 0.06 2 0.12 3 0.18 Threats Weight AS TAS AS TAS Law and order situation. 0.06 3 0.18 3 0.18 R& D therats 0.08 3 0.24 3 0.24 Smuggling of medicine 0.06 4 0.24 3 0.18 Sustainability risk identified in 2014 report is cyber-attacks, Third party relationship, inadequate strategies for Cloud, m-Health (use of mobile devices), e-Health (Use of electronic Devices and Social media. 0.02 3 0.06 3 0.06 Imitation of products/ fake medicines supplied under brands name can affect brand 0.05 4 0.20 3 0.15 Fluctuation in dollar rates 0.04 2 0.08 2 0.08 Avastin receives negative response from the FDA for use in breast cancer treatment. 0.03 3 0.09 3 0.09 Regulatory environment is becoming more & more stringent 0.04 3 0.12 4 0.16 Hard to forecast external factors 0.07 3 0.21 3 0.21 loss of patent protection in developing countries 0.05 2 0.10 2 0.10
  24. 24. Penetration in KPK Better employee programs to heighten perceived Value of salary, benefits, and self recognition Strengths Weight AS TAS AS TAS 1. Roche Pakistan is 42% share and global share is about 28% Brand 0.06 3 0.18 3 0.18 Brand heritage is high 0.07 3 0.21 4 0.28 Roche have very strong distribution network 0.06 4 0.24 4 0.24 81% of the employee are proud to work with Roche. 0.05 4 0.20 4 0.20 5. Roche Pakistan is leading brand of glucometer .i.e. Accu-Chek and it is present in Pakistan since last 20 years it almost cover the 45% market of Glucometer in Pakistan 0.05 3 0.15 3 0.15 It is no # 1 in Biotech, Oncology, diagnostic and hospital marketing. 0.05 3 0.15 3 0.15 World most sustainable company in life sciences 0.03 3 0.09 3 0.09 Continuous product development 0.04 1 0.04 2 0.08 4% Increase in Pharmaceutical sales from last year worldwide. 0.06 3 0.18 3 0.18 SHE safety, Security and environmental Protection is the integral part of Roche operations 0.03 2 0.06 2 0.06 Weaknesses Weight AS TAS AS TAS No local production. 0.05 3 0.15 2 0.10 Lack of coordination between industry and academia 0.06 0 0.00 1 0.06 No ATL activities .Roche is mostly involve in BTL activity. 0.04 2 0.08 2 0.08 Lack of infrastructure 0.06 4 0.24 4 0.24 Un-trained trained professionals 0.05 2 0.10 3 0.15 Lack of affordability 0.05 3 0.15 1 0.05 High internal pressure of cost adversely affects the developmental activities. 0.04 2 0.08 1 0.04 Roche products are imported, so import cost is higher than the local production 0.04 2 0.08 2 0.08 Lack of Promotional Campaign. 0.06 2 0.12 2 0.12 Lack of R& D in Pakistan 0.05 4 0.20 4 0.20 TOTALS 5.78 5.69
  25. 25. Recommendations: • Technological Advancements • Research and Development • Market penetration • Product Development. • Customer Care.

×